Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received

Siegel, 2018, Cancer statistics, 2018, CA Cancer J Clin, 68, 7, 10.3322/caac.21442 Hamdy, 2016, 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer, N Engl J Med, 375, 1415, 10.1056/NEJMoa1606220 Donovan, 2016, Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer, N Engl J Med, 375, 1425, 10.1056/NEJMoa1606221 Gnanapragasam, 2018, The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study, BMC Med, 16, 31, 10.1186/s12916-018-1019-5 Johnston, 2017, Mortality among men with advanced prostate cancer excluded from the ProtecT trial, Eur Urol, 71, 381, 10.1016/j.eururo.2016.09.040 Donovan, 2018, A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial, J Clin Epidemiol, 96, 35, 10.1016/j.jclinepi.2017.12.019 Donovan, 2019, Factors associated with trial recruitment, preferences and treatments received were elucidated in a comprehensive-cohort study, J Clin Epidemiol, 113, 200, 10.1016/j.jclinepi.2019.05.036 Fergusson, 2002, Postrandomisation exclusions: the intention to treat principle and excluding patients from analysis, BMJ, 325, 652, 10.1136/bmj.325.7365.652 Hollis, 1999, What is meant by intention to treat analysis? Survey of published randomised controlled trials, BMJ, 319, 670, 10.1136/bmj.319.7211.670 Newell, 1992, Intention-to-treat analysis: implications for quantitative and qualitative research, Int J Epidemiol, 21, 837, 10.1093/ije/21.5.837 Lane, 2014, Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial, Lancet Oncol, 15, 1109, 10.1016/S1470-2045(14)70361-4 D’Amico, 2002, Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era, Cancer, 95, 281, 10.1002/cncr.10657 D’Amico, 2006, Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer, J Urol, 176, S11 D’Amico, 1998, Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy, Cancer, 82, 1887, 10.1002/(SICI)1097-0142(19980515)82:10<1887::AID-CNCR11>3.0.CO;2-P Wei, 2000, Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer, Urology, 56, 899, 10.1016/S0090-4295(00)00858-X Donovan, 2000, Scoring the short form ICSmaleSF questionnaire, J Urol, 164, 1948, 10.1016/S0022-5347(05)66926-1 Metcalfe C. ProtecT study analysis plan v.10 signed 2015. https://research-information.bristol.ac.uk/files/55264058/ProtecT_Study_Analysis_Plan_V_1.0_signed.pdf. Rubin, 1976, Inference and missing data, Biometrika, 63, 581, 10.1093/biomet/63.3.581 Smith, 2018, Apalutamide treatment and metastasis-free survival in prostate cancer, N Engl J Med, 378, 1408, 10.1056/NEJMoa1715546 Hussain, 2018, Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer, N Engl J Med, 378, 2465, 10.1056/NEJMoa1800536 Beaver, 2018, Metastasis-free survival—a new end point in prostate cancer trials, N Engl J Med, 378, 2458, 10.1056/NEJMp1805966 NICE. Prostate cancer diagnosis and management 2014; 19 Jan 2017. https://www.nice.org.uk/guidance/CG175. Kasivisvanathan, 2018, MRI-targeted or standard biopsy for prostate-cancer diagnosis, N Engl J Med, 378, 1767, 10.1056/NEJMoa1801993 Martin, 2018, Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial, JAMA, 319, 883, 10.1001/jama.2018.0154 Klotz, 2015, Long-term follow-up of a large active surveillance cohort of patients with prostate cancer, J Clin Oncol, 33, 272, 10.1200/JCO.2014.55.1192 Bokhorst, 2015, Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers, Eur Urol, 68, 814, 10.1016/j.eururo.2015.06.012 Sartor, 2018, Metastatic prostate cancer, N Engl J Med, 378, 645, 10.1056/NEJMra1701695